A pilot study of the use of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction

Bilal Chughtai, Melissa A. Laudano, Claire Dunphy, Richard Lee, Steven A. Kaplan, Alexis Te

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To assess the efficacy of long-acting fesoterodine on persistent lower urinary tract symptoms in men who have had previous surgical treatment for bladder outlet obstruction (BOO). Materials and methods: Seventeen patients with overactive bladder (OAB) secondary to BOO, persisting for 3 months after the obstruction was surgically relieved, were treated with fesoterodine. Follow up was performed at 2 months, 3 months, and 7 months. The primary endpoint was change in the International Prostate Symptom Score (IPSS). The secondary endpoints were change in the maximum flow rate (Qmax) and postvoid residual (PVR). Results: Patients receiving fesoterodine demonstrated trends for improvement in mean nocturia episodes (3.2-2.6, p=0.065), IPSS irritative subscore (6.2-2.0, p=0.066), and quality of life score (4.2-3.5, p=0.067) over 7 months of follow up. There was also a reduction in the mean IPSS score which was not significant over time (18.8-15.1, p=0.183). There was no significant change observed in Qmax or PVR. Six patients (33%) had significant side effects and did not complete the study. Conclusion: Patients with persistent OAB symptoms after surgical treatment of BOO displayed possible reductions in the IPSS, IPSS irritative subscore, and mean number of nocturia events after 7 months of follow up, as well as trends for an increased quality of life when treated with fesoterodine. Larger trials are needed to help characterize the utility of fesoterodine in the treatment of persistent lower urinary tract symptoms after surgical treatment of benign prostatic hyperplasia.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalUrological Science
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Urinary Bladder Neck Obstruction
Overactive Urinary Bladder
Prostate
Nocturia
Lower Urinary Tract Symptoms
Quality of Life
Prostatic Hyperplasia
Therapeutics
fesoterodine

Keywords

  • Benign prostatic hyperplasia
  • Bladder outlet obstruction
  • Detrusor overactivity
  • Fesoterodine
  • Overactive bladder

ASJC Scopus subject areas

  • Urology

Cite this

A pilot study of the use of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction. / Chughtai, Bilal; Laudano, Melissa A.; Dunphy, Claire; Lee, Richard; Kaplan, Steven A.; Te, Alexis.

In: Urological Science, Vol. 26, No. 1, 01.01.2015, p. 38-40.

Research output: Contribution to journalArticle

@article{0087c06e89c24d30b322c2af30407ff7,
title = "A pilot study of the use of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction",
abstract = "Objective: To assess the efficacy of long-acting fesoterodine on persistent lower urinary tract symptoms in men who have had previous surgical treatment for bladder outlet obstruction (BOO). Materials and methods: Seventeen patients with overactive bladder (OAB) secondary to BOO, persisting for 3 months after the obstruction was surgically relieved, were treated with fesoterodine. Follow up was performed at 2 months, 3 months, and 7 months. The primary endpoint was change in the International Prostate Symptom Score (IPSS). The secondary endpoints were change in the maximum flow rate (Qmax) and postvoid residual (PVR). Results: Patients receiving fesoterodine demonstrated trends for improvement in mean nocturia episodes (3.2-2.6, p=0.065), IPSS irritative subscore (6.2-2.0, p=0.066), and quality of life score (4.2-3.5, p=0.067) over 7 months of follow up. There was also a reduction in the mean IPSS score which was not significant over time (18.8-15.1, p=0.183). There was no significant change observed in Qmax or PVR. Six patients (33{\%}) had significant side effects and did not complete the study. Conclusion: Patients with persistent OAB symptoms after surgical treatment of BOO displayed possible reductions in the IPSS, IPSS irritative subscore, and mean number of nocturia events after 7 months of follow up, as well as trends for an increased quality of life when treated with fesoterodine. Larger trials are needed to help characterize the utility of fesoterodine in the treatment of persistent lower urinary tract symptoms after surgical treatment of benign prostatic hyperplasia.",
keywords = "Benign prostatic hyperplasia, Bladder outlet obstruction, Detrusor overactivity, Fesoterodine, Overactive bladder",
author = "Bilal Chughtai and Laudano, {Melissa A.} and Claire Dunphy and Richard Lee and Kaplan, {Steven A.} and Alexis Te",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.urols.2014.06.003",
language = "English (US)",
volume = "26",
pages = "38--40",
journal = "Urological Science",
issn = "1879-5226",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A pilot study of the use of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction

AU - Chughtai, Bilal

AU - Laudano, Melissa A.

AU - Dunphy, Claire

AU - Lee, Richard

AU - Kaplan, Steven A.

AU - Te, Alexis

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To assess the efficacy of long-acting fesoterodine on persistent lower urinary tract symptoms in men who have had previous surgical treatment for bladder outlet obstruction (BOO). Materials and methods: Seventeen patients with overactive bladder (OAB) secondary to BOO, persisting for 3 months after the obstruction was surgically relieved, were treated with fesoterodine. Follow up was performed at 2 months, 3 months, and 7 months. The primary endpoint was change in the International Prostate Symptom Score (IPSS). The secondary endpoints were change in the maximum flow rate (Qmax) and postvoid residual (PVR). Results: Patients receiving fesoterodine demonstrated trends for improvement in mean nocturia episodes (3.2-2.6, p=0.065), IPSS irritative subscore (6.2-2.0, p=0.066), and quality of life score (4.2-3.5, p=0.067) over 7 months of follow up. There was also a reduction in the mean IPSS score which was not significant over time (18.8-15.1, p=0.183). There was no significant change observed in Qmax or PVR. Six patients (33%) had significant side effects and did not complete the study. Conclusion: Patients with persistent OAB symptoms after surgical treatment of BOO displayed possible reductions in the IPSS, IPSS irritative subscore, and mean number of nocturia events after 7 months of follow up, as well as trends for an increased quality of life when treated with fesoterodine. Larger trials are needed to help characterize the utility of fesoterodine in the treatment of persistent lower urinary tract symptoms after surgical treatment of benign prostatic hyperplasia.

AB - Objective: To assess the efficacy of long-acting fesoterodine on persistent lower urinary tract symptoms in men who have had previous surgical treatment for bladder outlet obstruction (BOO). Materials and methods: Seventeen patients with overactive bladder (OAB) secondary to BOO, persisting for 3 months after the obstruction was surgically relieved, were treated with fesoterodine. Follow up was performed at 2 months, 3 months, and 7 months. The primary endpoint was change in the International Prostate Symptom Score (IPSS). The secondary endpoints were change in the maximum flow rate (Qmax) and postvoid residual (PVR). Results: Patients receiving fesoterodine demonstrated trends for improvement in mean nocturia episodes (3.2-2.6, p=0.065), IPSS irritative subscore (6.2-2.0, p=0.066), and quality of life score (4.2-3.5, p=0.067) over 7 months of follow up. There was also a reduction in the mean IPSS score which was not significant over time (18.8-15.1, p=0.183). There was no significant change observed in Qmax or PVR. Six patients (33%) had significant side effects and did not complete the study. Conclusion: Patients with persistent OAB symptoms after surgical treatment of BOO displayed possible reductions in the IPSS, IPSS irritative subscore, and mean number of nocturia events after 7 months of follow up, as well as trends for an increased quality of life when treated with fesoterodine. Larger trials are needed to help characterize the utility of fesoterodine in the treatment of persistent lower urinary tract symptoms after surgical treatment of benign prostatic hyperplasia.

KW - Benign prostatic hyperplasia

KW - Bladder outlet obstruction

KW - Detrusor overactivity

KW - Fesoterodine

KW - Overactive bladder

UR - http://www.scopus.com/inward/record.url?scp=84924912927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924912927&partnerID=8YFLogxK

U2 - 10.1016/j.urols.2014.06.003

DO - 10.1016/j.urols.2014.06.003

M3 - Article

VL - 26

SP - 38

EP - 40

JO - Urological Science

JF - Urological Science

SN - 1879-5226

IS - 1

ER -